
Putting patients at the center

Innovative medicines increase the chances of recovery, improve quality of life and create new treatment options. To ensure patients benefit from these medical advances, broad and rapid access to new treatments is essential. However, this access has got progressively worse in Switzerland in recent years and is still under pressure: international developments such as the US' most-favored-nation (MFN) drug pricing policy are significantly exacerbating the existing problems regarding the reimbursement of innovative medicines. This makes it all the more important that Switzerland creates an attractive environment so that patients can continue to benefit at an early stage from innovative medicines in the future.

Supply is under pressure




Compared to Germany, **only half** of new, innovative medicines were equally available to all patients in 2024 (EFPIA Patients W.A.I.T. Indicator 2025 survey).

Source: Presentation by Interpharma with EFPIA Patients W.A.I.T. Indicator surveys 2018–2025. Comparison of EFPIA WAIT 2018 (EMA N=165 approved pharmaceuticals 100%) vs. 2025 (N=168, 100%).

The Swiss think action is needed

Assessment of availability of innovative medicines in Switzerland compared to Germany.

72% of voters consider the limited access to innovative medicines to be a problem.



Source: gfs.bern, Health Monitor (2026)

People want innovative medicines


+CHF 33	+CHF 17	- CHF 58	- CHF 64
Availability	**Access**	**Availability**	**Access**
from 50% to 90%	from seven months to immediately	from 50% to 30%	from seven to 24 months
IMPROVEMENT	IMPROVEMENT	DETERIORATION	DETERIORATION

Willingness to pay per month for changes in access via mandatory health insurance. Source: Swiss Economics (2026)

People want better access to innovative medicines and not a deterioration. The study by Swiss Economics (2026) shows that deteriorations in access to innovative medicines outweigh improvements of the same size.

Interpharma | Petersgraben 35 | P.O. Box| CH 4009 Basel | +41 61 264 34 00 | info@interpharma.ch | www.interpharma.ch | Association of Research-Based Pharmaceutical Companies in Switzerland

But supply is under pressure



- **7 out of 22** new active substances (NAS), i.e. **a third**, were **not** submitted to the FOPH for reimbursement by health insurers due to the US most-favored-nation (MFN) system.
- In addition, **three** new active substances **were not submitted to Swissmedic at all** due to the MFN system.

Source: Interpharma member survey (2026)

MFN in brief		
	Linking US and European prices • Drug prices will be linked to G7 (excl. US) prices, including DK and CH, and thus lowered.	**Switzerland at PPP in the reference basket** • The US references Swiss net prices (after deduction of rebates) adjusted for purchasing power parity (PPP).
	Expansion of MFN to the entire US market • New drugs will only be imported into the US at the reference price.	**After Trump** • Republicans and Democrats want to lower US drug prices.

What's important now

Secure early access

A pricing process that reflects current international conditions and guarantees patients access to innovative medicines is needed.

Take patient benefits into account adequately

The medical advances made by new therapies for patients must be adequately taken into account when decisions are made.

Consider international implications

Health policy decisions increasingly have an international impact. They must therefore also be assessed in terms of innovation, security of supply and access to innovative medicines.

Laying the groundwork for the future

Patients should continue to benefit from medical advances at an early stage in the future. This requires a pricing process that takes into account the current geopolitical context and appropriately rewards innovation.

Interpharma | Petersgraben 35 | P.O. Box| CH 4009 Basel | +41 61 264 34 00 | info@interpharma.ch | www.interpharma.ch | Association of Research-Based Pharmaceutical Companies in Switzerland